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MitochondriaTranslocations of regulator proteins from or to the mitochondria are key events in apoptosis regulation.
NOA36/ZNF330 is a highly evolutionary conserved protein with a characteristic cystein-rich domain. In this
work we address its mitochondrial localization and we demonstrate that a blockage of endogenous NOA36/
ZNF330 expression by small-interfering RNA (siRNA) reduced apoptotic response to etoposide (ETO),
camptothecin (CPT) and staurosporine (STS) but not to CH11 anti-Fas antibody or tumour-necrosis-factor-
related apoptosis-inducing ligand (TRAIL) in HeLa cells. In contrast, when ectopically expressed in the
cytoplasm, NOA36/ZNF330 induces apoptotic cell death. We also found that the domain responsible for this
proapoptotic activity is located its cystein-rich region. We propose that NOA36/ZNF330 is translocated from
the mitochondria to the cytoplasm when apoptosis is induced and that it contributes to cytochrome c release.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Apoptosis or selective cell suicide is a crucial process required for
normal embryo development, maintenance of tissue homeostasis and for
proper function of the immune system [1]. A deﬁcient regulation of this
process underlies many diseases; for example, failure of cells to initiate
apoptosis in response to DNA damage has been implicated in the
development and progression of cancer [2,3], whereas inappropriate
activationof apoptosis is thought tobe a contributing factor inAlzheimer's
and Parkinson's diseases [4,5]. Apoptosis is triggered by a cascade of
proteolytic activation of caspase proteases that eventually ends in the
digestion of cell proteins, nuclear DNA degradation, and cell death [6].
The molecular machinery for caspases activation can be induced
by two main pathways: the “death receptors pathway,” activated by
extracellular signals and mediated by caspase-8 [7,8] and the
“intrinsic pathway,” which is induced by several intracellular stress
conditions. The mitochondrion is a key organelle in the regulation of
the latest [9] and many regulators like the antiapoptotic proteins of
the Bcl-2 family, including Bcl-2 and Bcl-XL, are permanently located
at the mitochondria and preserve mitochondrial integrity [10].
However migration of regulatory molecules from or to the mitochon-icina, Biotecnología y Salud
s/n, 11510 Cádiz, Spain. Tel.:
ll rights reserved.dria is a frequent feature in apoptosis regulation. For example, some
proapoptotic members of this family such as Bax [11] and the BH3-
only proteins Bad [12], Bid [13], Bim [14] or Bmf [15] move from other
cellular compartments to the mitochondria in response to apoptotic
stimuli. These events result in mitochondrial pore formation and the
release of cytochrome c from the mitochondria into the cytosol [16–
18], where it binds to Apaf1 to form an oligomeric assembly called
“apoptosome,” which recruits and activates caspase-9 and allows the
activation of effectors caspases such as caspase-3 [19]. Cytochrome c
is not the only protein released from mitochondria during apoptosis,
for instance Smac-Diablo [20,21], HtrA2/Omi [22,23] and ARTS [24]
are mitochondrial proteins liberated into the cytosol when cells
undergo apoptosis, while AIF [25] and Endonuclease G [26,27] are also
normally conﬁned to the mitochondria but they translocate to the
nucleus when apoptosis is induced. Once they are released from the
mitochondria, all these proteins actively promote apoptotic cell death.
Molecular studies of many human autoantigens have demonstrat-
ed the important function of these proteins and have revealed new
cellular mechanisms [28]. In this work we investigate the subcellular
localization and function of NOA36 (Nucleolar Autoantigen-36 kDa)
also named ZNF330. This is a protein highly preserved during the
evolution that was previously described as a nucleolar autoantigen.
NOA36 is widely distributed in human tissues with signiﬁcantly
higher expression levels in heart and skeletal muscle [29]. The human
NOA36 gene was mapped by FISH to chromosome 4q31.1 q31.2 and is
comprised of 10 exons and spans 16 kb of genomic DNA [30]. In spite
1877I.S. de Melo et al. / Biochimica et Biophysica Acta 1793 (2009) 1876–1885its high grade of homology throughout distant phyla, no function,
either at cell or at organism level, has been associated to NOA36 so far.
Interestingly NOA36 was identiﬁed as a tyrosine kinase target in
Jurkat cells in a recent proteomic study designed to detect tyrosine
kinases substrates [31].
Here we show that NOA36 normally localizes at the mitochondria
in mammalian cells and that knockdown of NOA36 by RNAi reduces
the apoptotic response to ETO, CPT and STS but not to the death
receptor ligands anti-Fas antibody and TRAIL. We also show that
NOA36 is translocated from the mitochondria into cytoplasm when
apoptosis is triggered. Furthermore, when ectopically expressed in
the cytoplasm, NOA36 induces cytochrome c release and caspase-3
activation. This apoptotic phenotype is reverted by over-expression of
Bcl-2 and Bcl-XL. These results suggest that NOA36 is amediator of the
mitochondrial apoptotic pathway.
2. Materials and methods
2.1. Cell lines, culture conditions, drugs treatments and transfections
HeLa and CHO were cultured in Dulbecco's modiﬁed Eagle's
medium supplemented with 10% foetal bovine serum and 100 U/ml
penicillin and 100 μg/ml streptomycin at 37 °C in a CO2 incubator. For
drugs treatments, HeLa cells were exposed to ETO (from SIGMA)
(25 μM for 48 h), CPT (from SIGMA) (20 μM for 48 h), STS (from
SIGMA) (0.25 μM for 5 h), TRAIL (from Peprotech) (100 ng ml−1 for
5 h) or anti-Fas antibody (CH11 clone) (from Beckman Coulter)
(250 ng ml−1 for 5 h). Transient transfection of HeLa cells were
performed using 6 μl of jetPEI (Polyplus), and 1.8 μg of plasmid inFig. 1. ClustalW alignment of NOA36 amino acids sequences in species from different phyla. S
sapiens (Hs), avian Gallus Gallus (Gg), amphibian Xenopus laevis (Xl), ﬁsh Danio rerio (Dr)
Conserved amino acids in at least three species are shaded in grey. A putative bipartite nuc
indicated in white on black background. Other conserved cysteine (asterisk) and histidine (t
amino acids (D and E) in the polyacidic carboxyl terminal domain (from amino acids 260 to 3
two arrowheads.35mmplates, according to themanufacturer's instructions. Cells were
plated 24 h before transfections.
2.2. Subcellular fractionation and proteinase K digestion
Approximately 5×106 cells were seeded per 100-mm dish. On the
next day, cells were scraped and washed once with ice-cold
phosphate-buffered saline pH 7.4 (PBS). Low salt homogenization
buffer (LS-HB) containing 10 mM TRIS, pH 6.7, 10 mM KCl, 0.15 mM
MgCl2 was added (600 μl of LS-HB/dish) and left 10 min on ice. The
cells were homogenized by 30 strokes with a Dounce homogenizer
and by passing 15 times through an 18-G needle and then sucrose was
added to a ﬁnal concentration of 0.25 M. The homogenate was
centrifuged twice at 1500 g for 3 min at 4 °C. The pellet represented
the nuclear fraction. The supernatant was centrifuged at 5000 g at 4 °C
for 10 min, resulting in the mitochondria fractions (pellet). The
supernatant was centrifuged at 100,000 g for 1 h at 4 °C to collect the
cytosolic fraction (supernatant). The cytosolic supernatant and the
mitochondrial and nuclear pellets were fractionated on SDS-PAGE for
subsequent immunoblot analysis. For proteinase K partial digestions,
mitochondria pellets were resuspended in 60 μl of PBS pH 7.4 and
incubated with proteinase K (5 μg/ml) for 5 min, then 1 mM PMSF
was added and the mitochondria were pelleted, dissolved in sample
buffer and resolved by SDS-PAGE.
2.3. Immunostaining
For indirect immunoﬂuorescence staining, cells grown on cover-
slips were washed with PBS and ﬁxed in cold acetone for 10 min atpecies are indicated by the following abbreviations from top to bottom: mammal Homo
, insect Drosophila melanogaster (Dm) and the ﬁlarial nematode Brugia malayi (Bm).
lear localization signal is boxed at the amino terminal. The conserved CXXC motifs are
wo dots) residues in all the sequences are indicated. Note the high proportion of acidic
20 in the human protein). Phosphorylated Tyr residues in Jurkat cells are indicated with
Fig. 2. NOA36 is localized at the nucleoli and the mitochondria of mammalian cells at interphase. (a) Immunoﬂuorescence analysis on HeLa and CHO cells using a crude polyclonal
serum. In green, NOA36 immunodetection; in blue, DAPI chromatin staining. Nucleoli are indicated with arrowheads. The merged images show NOA36 and nucleoli colocalization.
(b) Immunoﬂuorescence analysis on HeLa and CHO cells using afﬁnity-puriﬁed NOA36 IgGs. In red, NOA36 immunodetection. In green, ATP synthase immunodetection, showing
mitochondria staining. In blue, DAPI chromatin staining, in which nucleoli can be appreciated (arrowhead). Merged image of the triple ﬂuorescent labeling shows co-localization of
NOA36 and the mitochondrial marker. Note that nucleolar staining is visible in CHO (arrowheads) but not in HeLa cells, probably due to a lower accumulation of NOA36 in HeLa
nucleoli. Bars, 10 μm. (c) Immunoblot analysis reveals NOA36 retention in mitochondrial and nuclear fractions. Protein extracts were divided into cytosol (lane C), mitochondrial
(lane M) and nuclear (lane N) fractions and analysed by Western blot using afﬁnity-puriﬁed anti-NOA36 IgGs. The quality of the fractionation is veriﬁed by controlling the
distribution of speciﬁc subcellular markers (COX-IV as mitochondria speciﬁc marker, and histone H1 as nuclear speciﬁc marker). (d) Partial proteinase K treatment indicates that
NOA36 is located on the outside of the outer mitochondrial membrane. Bcl-2 is located in the external membrane, cytochrome c, located in the intermembrane space and COX-IV
complex, in the inner mitochondrial.
1878 I.S. de Melo et al. / Biochimica et Biophysica Acta 1793 (2009) 1876–1885−20 °C (anti-NOA36 and anti-Flag antibodies) or 4% paraformalde-
hyde before permeabilization with 0.1% Triton X-100 (anti-active
caspase-3, anti-cytochrome c and anti-ATP synthase antibodies). Cells
were then washed with PBS and incubated with primary antibodies
diluted in PBS (1:10 of immunoafﬁnity-puriﬁed anti-NOA36 IgGs;
1:100 of anti-ATP synthase-subunit-α 7H10 (Molecular Probes);
1:500 of anti-Flag M2 (SIGMA); 1:1000 of anti-active caspase-3
(SIGMA) and 1:80 of anti-cytochrome c, clone 6H2B4, from AbCam) at
37 °C for 45 min. Cells were then washed with PBS for 30 min at room
temperature and incubated with Alexa ﬂuor 488 or 555-labeled
secondary antibodies (Molecular Probes) at 37 °C for 45 min. Finally,Fig. 3. Downregulation of NOA36 desensitizes cells to ETO, CPT and STS-mediated apoptosis
of NOA36.Western blot analysis of NOA36 expression in HeLa cells transfected with an equim
NOA36 expression in non transfected cells is also shown (lane C). (b) Knockdown of endogen
or anti-Fas antibody treatments. HeLa cells were transfected with NOA36 siRNAs or EGFP siR
anti-Fas antibody. Apoptotic cells were analysed by FACS using an antibody against the activ
where M1 gates active caspase-3 positive cells respect to untreated cells (diagram not shown
bars are standard deviation of themean. On the right of each diagram, a proﬁle of caspase-3 a
(N) and α-tubulin (α-T) are also shown for each experiment. Signiﬁcant differences (Pb0.0
NOA36 in normal control cells (lane C) and ETO (lane ETO) and TRAIL (lane TRAIL) treated H
control, ETO and TRAIL treated cells. Immunoblots from three different experiments were
normalize. Signiﬁcant differences (Pb0.05) are marked by asterisks (⁎). (d) Immunolocaliza
cells. In red, mitochondrial marker (anti-ATP-synthase). In blue, DAPI to label chromatin. M
localizes at the mitochondria. However, cells treated with CTP, ETO and STS and TRAIL shocells were washed twice in PBS and mounted in PBS-glycerol
containing DAPI at 0.1 μg/ml. A Zeiss Axiophot microscope equipped
with a 63×NA 1.3 oil immersion objective was routinely used. Images
were taken using a SPOT Camera (Diagnostic Instruments Inc.) and
processed using Adobe Photoshop software.
2.4. Western blot analysis
Protein lysates from total cell extracts and subcellular fractions
from HeLa cells were separated on 15% SDS-polyacrylamide gels,
electrophoretically transferred to Nitrocellulose membranesand NOA36 is translocated to cytosol during apoptosis. (a) siRNA-mediated knockdown
olecular mix of two different siRNAs against NOA36 or with control siRNA against EGFP.
eous NOA36 protects against CPT, ETO and STS-induced apoptosis but not against TRAIL
NA (control) then grown in the presence or in the absence of CPT, ETO, STS, TRAIL and
e form of caspase-3. FACS histograms plots from representative experiments are shown,
). Graph represents the average of the percentage of caspase-3 active cells (n=3). Error
ctivation (C-3) in the different conditions is illustrated byWestern blot. Levels of NOA36
5) are marked by asterisks (⁎). (c) Immunoblot analysis of cytosolic and mitocondrial
eLa cells. On the right, a diagram showing the quantiﬁcation of mitochondrial NOA36 in
analysed. The mitochondrial loading marker COX-IV of the same sample was used to
tion of NOA36 (green) in non-treated (NTC) and CPT, ETO, STS and TRAIL treated HeLa
erge image of the triple labeling is shown. In non-treated and CPT HeLa cells NOA36
w a NOA36 diffuse cytoplasmic staining. Bars, 10 μm.
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IgGs (1:1000), anti-COX IV (1:1000 dilution of 20E8 from AbCam),
anti-histone H1 (1:100 of monoclonal 12C7, a gift of M.M. Valdivia),
anti-cytochrome c (1:3000 of 7H8 from Santa Cruz Biotechnology)
anti-α-−tubulin (1:3000 of DM1A from SIGMA) anti-active caspase-3
(1:500 of Asp175 from Cell Signalling) and anti-Bcl-2 (1:600 of C-2 5
from Santa Cruz Biotechnology). Following incubation of the
membranes with HRP-coupled secondary antibodies (SIGMA), pro-
teins were visualised by ECL detection kit (Roche). For Western blot
quantiﬁcation of NOA36 the software GeneTools (Syngene) was used.
2.5. Plasmids and constructs
Mammalian expression cytomegalovirus promoter-based vector
constructs encoding C-terminal tagged Flag-NOA36 (Invitrogen), N-
terminal tagged NOA36-EGFP (Clontech) and NOA36-Cherry (a gift of
Dr. R.Y. Tsien) were generated by PCR ampliﬁcation from the human
full-length NOA36 cDNA [29]. PCR products incorporated EcoRI site on
the 5′ end and the BamHI site on the 3′ end. Eight truncanted fusion
proteins containing amino acids 1–33, 40–320, 40–239, 33–85, 92–
139, 136–185, 178–239, 218–320 of NOA36 were expressed as fusion
proteins to EGFP. All constructs were sequenced. GFP-Bcl-2 and GFP-
Bcl-XL constructs are gifts from Dr. R. J. Youle.
2.6. Knockdown of endogenous NOA36 by siRNA and apoptosis
quantiﬁcation by FACS
Sense and anti-sense oligonucleotides corresponding to the
following cDNA sequences were purchased from SIGMA for NOA36:Fig. 4. NOA36 cytoplasmic ectopic expression induces apoptotic cell death in HeLa cells. (a)
with NOA36-EGFP. DAPI staining is shown to visualize nuclei. (b) Transfected cell showin
blebbing, characteristic features of apoptotic cell death. (c) Transient trasfection assay of a
panel, DAPI staining to visualize nuclei. Flag-NOA36 tagged protein is located in the nucleol
cytoplasmic NOA36-EGFP (black bar), nucleolar Flag-NOA36 (striped bar) or control empty
inhibitor reduces the rate of cellular death in cells expressing cytoplasmic NOA36-EGFP. The
and NOA36-EGFP transfectants grown in a normal medium (black bar) or in 100 μM z-V
transfection. (f) NOA36 cytoplasmic expression induces caspase-3 activation. On the left, NO
labeled with an antibody that speciﬁcally recognizes the active form of the caspase-3 (ce
Quantiﬁcation of active caspase-3 positive cells in NOA36-Cherry (black bar) and in Cherry
represent standard deviation of the mean. Signiﬁcant differences (n=4, Pb0.05) are markeCACUCAUGUCUCCGUUGU AdTdT (nucleotides 723–741) and
UUAGCU AAACAUCCAUGUAdTdT (nucleotides 1032–1050). HeLa
cells were transfected with Interferin (Polyplus) according to the
manufacturer's protocol in the presence of NOA36 siRNA or EGFP
siRNA (GCA AGC UGA CCC UGA AGU UCA U) as a control. Cells were
scraped 72 h after transfection and protein extracts were immuno-
bloted to evaluate knockdown of endogenous NOA36 or kept in
culture in the presence or in the absence of ETO, CPT, STS, TRAIL or
anti-Fas antibody. Then, were detached by trypsin-EDTA treatment,
washed in PBS and ﬁxed in 4% paraformaldehide (500 μl, 15 min, RT).
After an additional washing, permeabilization and staining with
phycoerytrin-conjugated rabbit polyclonal antibody against active
caspase-3 (Becton Dickinson) were performed in the same step
(100 μl 0.2% triton X-100, 1/20 antibody dilution, 30 min, RT, in the
dark). Finally cells were washed again and acquired in a FACScalibur
ﬂow cytometer (Becton Dickinson). Cells were gated on a forward/
side scatter plot and analyzed for active caspase-3 expression with
CellQuest software (Becton Dickinson).2.7. Cell death analysis by epiﬂuorescence in transfected cells
1×106 transfected HeLa cells seeded onto coverslips were grown
for 24–48 h before being ﬁxed in 4% paraformaldehyde–PBS for
20 min at room temperature, then permeabilised in 0.1% Triton X-100
and stained with 2-(4-amidinophenyl)-1H-indole-6-carboxamidine
(DAPI) (SIGMA), at room temperature for 2 min. Coverslips were then
mounted in PBS–glycerol for EGFP ﬂuorescence observation or
subjected to immunostaining with an anti-Flag antibody (SIGMA).
Approximately 400 transfected cells were counted for eachNOA36-EGFP is located in the cytoplasm. On the left panel, transient transfection assay
g signs of apoptosis. Note the condensed/fragmented chromatin and the membrane
Flag-NOA36 expressing vector on HeLa cells. On the left, Flag-NOA36 and on the right
i (arrowheads). Bars, 10 μm. (d) Quantiﬁcation of the cell death rate induced by either
pEGFP vector (white bar) at 24 and 48 h post-transfection. (e) z-VAD-fmk pan-caspase
graphic shows the death rate in transfected cells with pEGFP control vector (white bar)
AD-fmk supplemented medium (grey bar). Cells were monitored 24 and 48 h after
A-cherry transfected cells (upper panels) and cherry empty vector (lower panels) are
ntral panels). DAPI staining is also shown to visualize cells nuclei. Bars, 100 μm. (g)
(white bar) transfected cells 48 h after transfection. The error bars in (d), (e) and (g)
d by asterisks (⁎).
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microscope. Apoptotic cells were distinguished based on morpholog-
ical alteration typical of adherent cells undergoing apoptosis
(becoming rounded, having blebbing cytoplasm, and condensed
chromatin) or by immunoﬂuorescence with an antibody to the active
caspase-3 or with an antibody to cytochrome c. For analysis of caspase
inhibition, cells were treated with 100 μM z-VAD-FMK (SIGMA) 8 and
24 h after transfection.
2.8. Statistics
Comparisons between groups were performed with Student's t-
test for paired samples (two-tailed) (n≥3) and signiﬁcant differences
(pb0,05) were denoted by an asterisk.
3. Results
3.1. NOA36 is a highly evolutionary conserved protein
Since the ﬁrst cDNA encoding NOA36 sequence was published
[29], many EST and genome projects have been completed, which
allowed us to perform a more thorough analysis of the degree of
conservation of NOA36 during evolution. ClustalW alignment of
NOA36 protein sequences from different phyla allows now a better
understanding of the primary structure of this protein (Fig. 1). Besides
a very similar number of amino acids (from 313 to 322), three
different domains can be deduced in NOA36 protein. At both ends two
characteristic sequences can be predicted: a putative amino-terminal
nuclear localization signal and a poly-acidic region, with a 42% of Asp
and Glu residues in the last 60 amino acid carboxyl-terminal in the
human protein. However, the most characteristic feature of this
protein is a Cys-rich domain that consists of 214–216 amino acids
with at least 16% of Cys residues. The 29 Cys in the human protein are
arranged in the same relative position in all available orthologous
sequences, with nine Cys-X-X-Cys highly conserved motifs indicative
of several putative zinc ﬁngers. These motifs make NOA36 a potential
Zn ﬁnger protein with at least four Zn binding motifs. The striking
grade of homology throughout distant phyla of NOA36 proteins
prompted us to investigate this protein whosemolecular function was
unknown.
3.2. NOA36 protein is associated with the mitochondria and the
nucleolus
NOA36 was identiﬁed a decade ago as a nucleolar autoantigen in a
patient suffering from rheumatoid arthritis and its subcellular
localization was determined by indirect immunoﬂuorescence with a
speciﬁc polyclonal serum raised against the recombinant hamster
NOA36 [29]. These experiments demonstrated that NOA36 was
located predominantly but not exclusively at the nucleolus, with
some diffuse/punctuate cytoplasmic staining, in several mammalian
cell lines (Fig. 2a). Our ﬁrst aim was to investigate whether the
cytoplasmic staining of this polyclonal serum was genuine NOA36
localization. To address this point we afﬁnity puriﬁed speciﬁc anti-
NOA36 immunoglobulins (IgGs) using the human NOA36 recombi-
nant protein immobilized on sepharose beads. Immunoﬂuorescence
assays using the puriﬁed anti-NOA36 IgGs showed a pattern that
colocalized with a mitochondrial marker in mammalian cells (Fig.
2b). Although NOA36 could be detected at the nucleoli in CHO cells,
no nucleolar staining could be observed in HeLa, probably due to a
lower nucleolar NOA36 concentration in this cell line. Later obtained
polyclonal serum to NOA36 recombinant protein conﬁrmed its
mitochondrial localization (data not shown). Western blot assay
with the afﬁnity puriﬁed IgGs corroborated the mitochondrial and
nuclear NOA36 localization (Fig. 2c). In order to determine if NOA36
is located within the mitochondria or associated with the outermembrane of this organelle, we subjected a mitochondria extract to
limited proteinase K treatment, which results in digestion of proteins
located on the mitochondria cytosolic surface. This experiment
clearly demonstrated that NOA36 was digested by proteinase K, as
occurs with Bcl-2, a protein that is associated to the external
membrane (Fig. 2d). However, cytochrome c, which is located at the
intermembrane space and the COX IV complex, which is embedded
in the inner mitochondrial membrane, were resistant to proteolysis
under proteinase K digestion, indicating that the mitochondrial
external membrane remained intact throughout the experiment. We
therefore conclude that NOA36 is a mitochondrial protein very likely
associated with the outer layer of the external mitochondrial
membrane.
3.3. NOA36 downregulation reduces sensitivity to etoposide, camptothecin,
and staurosporine but not to anti-Fas antibody or TRAIL
Becausemitochondria play a key part in the regulation of apoptosis
we analyzed whether loss of function of NOA36 had any effect in this
process by suppressing expression of endogenous NOA36 by siRNA in
HeLa cells. After Western blot analysis we found that an equimole-
cular mix of two NOA36 siRNAs brought about a strong inhibition of
NOA36 expression whereas control siRNA against GFP had no effect
(Fig. 3a and Fig. 1 SM). To study a possible role of NOA36 in apoptosis,
we used ETO, CPT and STS as intrinsic pathway inducers and anti-Fas
antibody and TRAIL as death receptor ligands. We then analyzed
apoptosis by ﬂuorescence-activated cell sorting (FACS) with an
antibody to the active form of caspase-3, one the main apoptosis
effectors. We found reduced active-caspase-3 staining respect to
control siRNA for ETO, CTP and, in a lower extent, for STS treatments
(Pb0.05) but not for anti-FAS antibody or TRAIL exposure. Coherently
with FACS analysis, a diminution of caspase-3 activity was detected in
Western blot analysis of NOA36 siRNA treated cells in the ETO, CPT
and STS, but not after anti-Fas or TRAIL treatments (Fig. 3b). These
data together with NOA36 mitochondrial localization suggest a
proapoptotic role of NOA36 in the regulation of the mitochondrial
apoptotic pathway.
3.4. NOA36 migrates to cytoplasm during apoptosis
To study whether NOA36 mitochondrial localization is altered in
cells undergoing apoptosis, we analyzed the localization of NOA36 by
Western blot assays in cytosolic and mitochondrial extracts in HeLa
cells. NOA36 can be detected in the cytosolic fraction in the ETO and
TRAIL treated cells, but it is barely detectable in the cytosol of normal
control cells. On the other hand, quantiﬁcation by Western blottings
of mitochondrial NOA36 by normalizing with COX-IV mitochondrial
marker showed that NOA36 levels are 50% lower in ETO and 40%
lower in TRAIL than in non-treated control cells (Fig. 3c). This
translocation can be visualized by immunoﬂuorescence assays. Upon
apoptosis induction with ETO, CPT, STS and in a less extent in TRAIL,
NOA36 staining changed from a ﬁlamentous mitochondrial pattern to
a more diffuse cytoplasmic distribution whereas the mitochondrial
marker (ATP-synthase-subunit-α) still showed a mitochondrial
pattern (Fig. 3d).
3.5. Ectopic localization of NOA36 in the cytoplasm induces a high rate of
apoptotic cell death
We next asked whether NOA36 cytoplasmic localization might
have an active role in cell death or if it was just a consequence of the
mitochondrial disruption caused by apoptosis. To this end, we
investigated the effect of cytoplasmic NOA36 on cell survival by
using the fusion protein NOA36-EGFP. Transient transfection assays of
NOA36-EGFP in HeLa cells showed a cytoplasmic, but not nucleolar or
mitochondrial distribution (Fig. 4a). We also found the same
Fig. 5. Mapping of the domain responsible for NOA36 cell death induction. (a)
Schematic representation of the different constructs used for the mapping of NOA36
cell death domain. Cell death rate caused by these constructs at 48 h after transfection
are indicated at the right (n=3). Signiﬁcant differences (Pb0.05) respect to the empty
vector (EGFP) aremarked inwhite on grey background. All constructs represented are C
terminal fusion proteins to EGFP. In light grey the Cys rich domain (black bars represent
CXXC motives). The zinc ﬁnger domain responsible for the strongest cell death
induction (residues 92–139) is highlighted in dark grey. (b) Bar diagram showing cell
death rates induced by non-overlapping truncated proteins. The error bars represent
standard deviation of the mean. Signiﬁcant differences (n=3, Pb0.05) are marked by
asterisks (⁎).
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of EGFP (data not shown). It has been shown that expression of
native proteins fused to tag sequences or ﬂuorescence proteins, may
impair normal cellular localization of the fusion protein compared
with the endogenous form. This feature has previously been used to
study the effect of proapoptotic proteins when ectopically expressed
in other cellular compartments [32]. Transfected cells were
monitored for NOA36-EGFP ectopic expression and for nuclear
chromatin condensation by DAPI staining (Fig. 4b). We observed
that NOA36-EGFP cytoplasmic localization induced around 30% and
50% of cell death in transfected cells at 24 and 48 h after
transfection, respectively (Fig. 4d), but apoptosis rate reach 91.5%
at 96 h after transfection (Fig. 2 SM). On the other hand, the
quantiﬁcation of apoptosis in ﬁxed cells could underestimate the
rate of apoptosis due to the fact that HeLa terminal apoptotic cells
can be detached from coverslip (Fig. 2 SM). It has been described
that EGFP may aggregate within cells, which may have a toxic effect.
To check that cell death was speciﬁcally being caused by NOA36,
and not due to EGFP aggregates, we carried out similar experiments
using the red monomeric ﬂuorescent protein Cherry, which does not
to aggregate upon transfection [33]. Fusion protein NOA36-Cherry
also localized to the cytoplasm in HeLa cells and leaded to a similar
cell death rate when compared to NOA36-EGFP (data not shown).
To further conﬁrm that apoptosis was the cause of cell death, we
treated NOA36-EGFP transfectans with the cell permeable pan-
caspase inhibitor z-VAD-fmk [34] and monitored cell death as
previously described. As shown in Fig. 4e, this treatment reduced
signiﬁcantly the cell death rate (Pb0.05) to a level similar to that
observed in cells expressing EGFP alone.
We next investigated the relationship between NOA36 apo-
ptotic induction and caspase-3 activation by ﬂuorescence micros-
copy with an antibody against the active form of caspase-3 (Fig. 4f).
We detected that 36±4% of the NOA36-Cherry transfected cells
were active caspase-3 positive at 48 h after transfection versus
14±2% in cells transfected with the empty vector (Pb0.05)
(Fig. 4g).
Since native NOA36 is also localized in the nucleolus, we
monitored the cell death rate in cells expressing the tagged protein
Flag-NOA36. Flag-NOA36 is located at the nucleoli in most of the
transfected cells (Fig. 4c). In this case, cell death was not induced
upon transfection of Flag-NOA36 when compared with cells trans-
fected with the control plasmid (Fig. 4d). Overall, these data suggest
that cytoplasmic localization of NOA36 is not just an irrelevant
consequence of mitochondrial disruption during apoptosis; on the
contrary it is sufﬁcient to induce cell death.
4.6. The NOA36 cell death domain is located within the NOA36 cystein-
rich region
To identify the NOA36 domain that induced cell death, several
truncated NOA36-EGFP constructs were analyzed in transient
transfection assays by monitoring condensed chromatin as an
indicator of cell death. These studies indicated that, out of the 3
putative domains of the protein, only the cysteine-rich domain
consistently induced apoptosis. Truncated NOA36 proteins lacking
the N-terminal nuclear localization signal and/or polyacidic C-
terminal induced an even a higher cell death rate than the full
length protein (Fig. 5a). Moreover, overexpression of several non-
overlapping truncated NOA36 proteins within the cystein-rich
domain, fused to EGFP was used to determine which part of this
domain was sufﬁcient to induce apoptosis (Fig. 5b). We found that
only a putative zinc ﬁnger domain between amino acids 92–139
could signiﬁcantly induce apoptosis respect to the empty vector in
percentage similar to that caused by the full-length protein (Pb0.05).
We can therefore conclude that this sequence is the main responsible
for the cell death caused by NOA36.3.7. Apoptosis induced via NOA36 cytoplasmic expression is mediated by
cytochrome c release and is inhibited by Bcl-XL and Bcl-2
We subsequently asked whether NOA36 could activate caspase-3
via mitochondrial membrane permeabilization and cytochrome c
release, a decisive event of the intrinsic pathway of apoptosis. We
studied the fate of cytochrome c in NOA36-EGFP and EGFP transfected
HeLa cells by ﬂuorescence microscopy. We found three different
abnormal cytochrome c distributions: (1) non-ﬁlamentous but
condensed cytochrome c labeling, with normal round nuclei
(Fig. 6a); (2) diffuse cytochrome c labeled and nuclei with a
round shape and no condensed chromatin (Fig. 6b); (3) diffuse
cytochrome c staining and condensed and/or fragmented nuclei
(Fig. 6c). The quantiﬁcation by immunoﬂuorescence of the second
staining pattern, as representative of proapoptotic cells showed that
30±8% of the cells expressing NOA36-EGFP have proapoptotic
features 48 h after transfection versus a 2±0.7% of cells transfected
with the empty vector (Pb0.05) (Fig. 6d). Although these results
indicated that transfecting NOA36-EGFP in cells induced cytochrome
c release, it did not necessarily mean that NOA36-EGFP acts upstream
of the mitochondrial membrane permeabilization, since cytochrome
c release could also be due to a feedback mechanism of an event
caused by NOA36-EGFP after mitochondrial outer membrane
Fig. 6. NOA36 cytoplasmic expression induces cytochrome c release and its apoptotic effect is inhibited by Bcl-2 and Bcl-XL overexpression. (a–c) Triple ﬂuorescence with an anti-
cytochrome c antibody (left panels), NOA36-EGFP (central panels) and DAPI chromatin staining (right panels). Three different abnormal cytochrome c–chromatin patterns (labeled
with arrowheads) are detected in NOA36-EGFP transfected cells: (a) non-ﬁlamentous but condensed cytochrome c labeling and normal nuclei, (b) diffuse cytochrome c, nuclei with
a round shape and no condensed chromatin, (c) diffuse cytochrome c staining and condensed/fragmented nuclei. Bar, 10 μm. (d) Bar diagram showing the percentage of cells
showing pattern in (b) 48 h after transfection with EGFP (white bar), and NOA36-EGFP transfectants grown in a normal medium (grey bar) or in 100 μM z-VAD-fmk supplemented
medium (black bar). (e) Bar diagram indicating the cell death rate induced by transfection with NOA36-Cherry (white bar) and co-transfected with GFP-Bcl-XL (grey bar) or GFP-
Bcl2 (black bar). (f) Schematic representation of the proposed role for NOA36 in the mitochondrial apoptotic pathway. After apoptosis induction, NOA36 is released from
mitochondria. When located into cytoplasm, NOA36 acts upstream of cytochrome c to trigger the mitochondrial apoptotic pathway. The error bars in (d) and (e) represent standard
deviation of the mean. Signiﬁcant differences (n=5, Pb0.05) are marked by asterisks (⁎).
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acts upstream of the mitochondrial membrane permeabilization, we
also examined cytochrome c release when the mitochondrial
downstream pathway (caspases activation) was blocked by the pan
caspase-inhibitors z-VAD-fmk in NOA36-EGFP transfected cells. We
found that blocking downstream events to mitochondria permeabi-
lization by inhibiting all the caspases activity there was no decrease
in the proportion of cells with diffuse cytochrome c staining — as
could be expected if NOA36-EGFP acted downstream MOMP; on the
contrary, there was a remarkable increment (up to 58±9%) of this
staining pattern (Pb0.05) probably due to the accumulation of cells
in which MOMP have already occurred but with no other apoptotic
characteristics (i.e. nuclear fragmentation, blebbing cytoplasm, etc).
Another attribute of the apoptotic mitochondrial permeabilization
is that it can be blocked by over-expression of antiapoptotic
mitochondrial proteins like Bcl-2 and Bcl-XL [32]. We analysed this
feature by co-transfection of NOA36-Cherry and GFP-Bcl-2 or GFP-Bcl-
XL. In both cases, apoptosis was drastically reduced in double
transfectants (Pb0.05), although over-expression of Bcl-XL was
more efﬁcient and almost completely avoided all the apoptotic
activity of cytoplasmic NOA36-EGFP (Fig. 6e).
Altogether these data suggest that ectopic expression of cytoplas-
mic NOA36-EGFP causes a redistribution of cytochrome c from the
mitochondria to the cytoplasm, upstream mitochondrial permeabili-
zation to trigger the mitochondrial apoptotic pathway.5. Discussion
Elucidating the function of the intracellular signalling molecules
that mediate apoptosis will provide valuable insights into the
mechanisms of cell death and possible routes for treatment of
human diseases in which apoptosis regulation is impaired. Here we
characterize the proapoptotic activity of NOA36, a protein reported as
a nucleolar autoantigen 10 years ago but whose function remained
unknown. Our results demonstrate that the conserved NOA36 protein
is also localized in the mitochondria, very likely in association with
the cytosolic side of the outer membrane. Relatively little is known
about the mechanism of insertion and assembly of outer membrane
proteins (reviewed in ref. [35]). Like all known proteins located at the
mitochondrial outer membrane, NOA36 do not contain a canonical
cleavable N-terminal presequence, suggesting that it is likely bound to
mitochondrial protein(s). Since NOA36may be involved inMOMP, we
also investigated whether it bound to anti-apoptotic Bcl-2 family
members such as Bcl-2 or Bcl-XL; however, GST pull-down and
immunoprecipitation assays did not reveal direct interaction with
these mitochondrial proteins (data not shown). Our aim in a future
work is to study the interaction of NOA36 with others mitochondrial
proteins by antibody arrays of apoptotic proteins and/or by yeast two
hybrids.
We also show that NOA36 mitochondrial localization is dynamic,
as occurs with certain proteins which are not permanently anchored
1884 I.S. de Melo et al. / Biochimica et Biophysica Acta 1793 (2009) 1876–1885to the outer membrane but rather associate with the membrane in a
dynamic manner. In this sense, proteins located at other cellular
compartments can be also transported to the mitochondria. For
instance, it has been shown that during apoptosis, Bad can direct p53
speciﬁcally to mitochondria [36].
Since the pioneering work of Wang and coworkers identiﬁed
cytochrome c as a key component of the apoptosis pathway [17],
mitochondria have been central to apoptosis research. Due to NOA36
mitochondrial localization, we considered a possible function for
NOA36 in the programmed cell death process. Our results show that
downregulation of NOA36 expression desensitizes HeLa cells to CPT,
ETO and STS mediated apoptosis but not to the death receptors
ligands anti-Fas antibody or TRAIL. The most evident apoptotic
attenuationwas found after treatmentwith topoisomerases inhibitors
CPT and ETO, which generate nonrepairable protein-linked DNA
double-strand breaks. These results are suggestive of a proapoptotic
function of NOA36 linked to the mitochondrial death pathway and
probably with a more speciﬁc role in the apoptosis induced by DNA
damage. NOA36 is translocated from the mitochondria to the
cytoplasm during apoptosis in HeLa cells and we found a high
apoptosis-inducing activity when NOA36 is ectopically expressed in
cytosol but not in the nucleoli. Although translocation of NOA36 to the
cytoplasm was also found after TRAIL treatment, NOA36 seems to
have a minor role in the apoptosis activated by extracellular signals,
since downregulation of NOA36 has no effect in apoptosis induced by
anti-Fas antibody or TRAIL.
The translocation of proapoptotic proteins like SMAC/DIABLO,
ARTS and HtrA2/Omi from the mitochondria to the cytosol is a
relevant feature in apoptosis activation. However, there are two
important differences between these proteins and NOA36 proapop-
totic activity. Firstly these proteins are located at the intermitochon-
drial membrane space, whereas NOA36 is located at the cytosolic side
of the outer mitocondrial membrane. Secondly, whilst these media-
tors are liberated to the cytosol as a consequence of mitochondrial
pore formation, our data would suggest that NOA36 could activate the
apoptotic intrinsic pathway upstream of mitochondrial outer mem-
brane permeabilization, since cytochrome c release – an event
secondary to mitochondrial permeabilitation – can be detected in
the cytoplasm in a signiﬁcant proportion of transfected cells
ectopically expressing cytoplasmic NOA36-EGFP. Nevertheless, to
demonstrate that endogenous NOA36 is released upstream cytchrome
c release, kinetic studies should be carried out with different apoptosis
inductors. This will help us to deﬁnitely determine whether or not
NOA36 is released from the mitochondria before cytochrome c. In this
case, NOA36 could represent a new kind of mitochondrial proapop-
totic protein with a possible role in upstream events to mitochondrial
pore formation, either via activation of molecules involved in pore
formation (Bax, Bak) or by activating one or more of the BH3-only
proteins that eventually could cause pore formation and cytochrome c
release (Fig. 6f).
The analysis of apoptosis induction of several NOA36 truncated
proteins has revealed that a short amino acid sequence, with no
signiﬁcant homology with others proapoptotic domains, is the main
responsible for the cell death inducing properties of NOA36. This
sequence contains amino acids from 92 to 139 in the human protein
and could form a Zn ﬁnger domain, with two C-X-X-Cmotives at C and
N ends. This apoptotic activity in a protein containing (C-X-X-C)
motives contrast with the fact that, many cellular protective proteins
contain this motif in their active sites (e.g., thioredoxin, peroxir-
edoxin, protein disulﬁde, etc.).
In summary, our ﬁndings demonstrate that NOA36 is a mitochon-
drial protein located on the cytosolic side of the outer membrane that
is released from mitochondria during apoptosis and becomes part of
the machinery that brings about cell death. To our knowledge, this is
the ﬁrst evidence showing that NOA36 ha functional relevance within
the cell. Its association with cell death makes this protein aninteresting candidate to study in biological processes, where apopto-
sis is impaired. Further research will elucidate the molecular
mechanism underlying the apoptotic activity of NOA36.
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